6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2018

Commission File Number: 001-31368

SANOFI

(Translation of registrant’s name into English)

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):              

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):              

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ☐            No  ☒

If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-            

In June 2018, Sanofi issued the press release attached hereto as Exhibit 99.1 which is incorporated herein by reference.

Exhibit List

Exhibit No.	Description
Exhibit 99.1	Press release dated June 19, 2018: Sanofi appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice President, Chief Financial Officer

2

Exhibit Index

Exhibit No.	Description
Exhibit 99.1	Press release dated June 19, 2018: Sanofi appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice President, Chief Financial Officer

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: June 20, 2018	SANOFI
	By	/s/  Alexandra Roger
		Name: Alexandra Roger
		Title:   Head of Securities Law and Capital Markets

4

EX-99.1

Exhibit 99.1

Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY)

Sanofi appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice President, Chief Financial Officer

Paris – June 19, 2018 - Sanofi has appointed Jean-Baptiste Chasseloup de Chatillon as Executive Vice President, Chief Financial Officer (CFO) and Member of the Executive Committee, effective October 1^st 2018. He will join Sanofi September 1^st to ensure a smooth transition with Jérôme Contamine who will retire on September 30^th, after more than 9 years of distinguished service at Sanofi.

Mr. Chasseloup de Chatillon most recently served as Chief Financial Officer and Executive Vice-President for PSA Group. In this capacity he was also a member of the Managing Board and of the Executive Committee. Throughout his tenure at PSA Group, he held various management positions in finance (Treasurer in Spain, Chief Financial Officer in the United Kingdom) and in sales and marketing (Citroen Belgium Managing Director.) He was also Chairman of the Board of Banque PSA Finance (BPF) from 2012 to June 2016. He has been a member of the Peugeot S.A. Managing Board since 2012.

“Jean-Baptiste is an experienced CFO who has been part of the impressive turnaround of PSA Group. His track record of successfully driving finance across different businesses and geographies throughout his career will be of great value to lead our very experienced team around the world,” says Olivier Brandicourt, Chief Executive Officer at Sanofi. “I would like to express my thanks and gratitude to Jerome Contamine for his excellent service to Sanofi during the company’s transformation over the past decade. He has been a highly committed and trusted business partner to me and to my executive team.”

A citizen of France, Mr. Chasseloup de Chatillon holds a Master from Paris Dauphine and studied Finance in the UK (Lancaster University).

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

Media Relations Contact
Laurence Bollack
Tel.: +33 (0)1 53 77 46 46
mr@sanofi.com Investor Relations Contact
George Grofik
Tel.: +33 (0)1 53 77 45 45
ir@sanofi.com